Astria Therapeutics (ATXS) Jefferies London Healthcare Conference 2024 summary

Strategic focus and pipeline overview

• Focused on allergy and immunology, developing therapies with established mechanisms and aiming for best-in-class or first-choice status based on efficacy, safety, and low treatment burden.

• Pipeline includes navenibart for hereditary angioedema (HAE) and STAR-0215 for atopic dermatitis, both aligning with the strategy.

STAR-0215 (navenibart) in HAE: Clinical progress and differentiation

• Phase 1b/2 ALPHA-STAR trial showed 90%-96% reduction in HAE attacks with one or two doses over six months.

• Full results from 16 patients expected soon, with anticipated 80%-90% attack rate reduction at three and six months.

• Differentiates from Takhzyro by offering dosing every three or six months, potentially improving patient quality of life and reducing injection pain.

• Phase 3 trial planned to start in Q1 2025, with global regulatory engagement and inclusion of adolescents.

• Market opportunity for HAE prophylactic therapies projected to exceed $4.5 billion by 2027.

Competitive landscape and physician priorities

• Navenibart leverages a trusted mechanism with robust efficacy and low treatment burden, aiming to be first-choice therapy.

• Physicians prioritize efficacy, treatment burden, and safety, with 80%-90% attack reduction as a key benchmark.

• Anticipated decrease in on-demand therapy use as prophylactic options improve.

• Manufacturing strategy emphasizes experienced teams and reliable CDMOs to avoid setbacks seen in competitors.